Charles Antoine Janssen shares his views on how investments aimed at improving the health of the most vulnerable populations in the world can still generate adequate financial returns for the investors. Charles Antoine Janssen is vice chair of UCB, a global biopharmaceutical company headquartered in Belgium. And he's also managing partner of Kois https://koisinvest.com and Healthquad. Charles Antoine has experience in fundraising for social impact funds as well as investing the money raised in companies that want to solve societal problems. He shares his views on how investments aimed at improving the health of the most vulnerable populations in the world can still generate adequate financial returns for the investors.
https://www.ucb.com
https://healthquad.in
All content for Health Innovation and Entrepreneurship is the property of Oxford University and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Charles Antoine Janssen shares his views on how investments aimed at improving the health of the most vulnerable populations in the world can still generate adequate financial returns for the investors. Charles Antoine Janssen is vice chair of UCB, a global biopharmaceutical company headquartered in Belgium. And he's also managing partner of Kois https://koisinvest.com and Healthquad. Charles Antoine has experience in fundraising for social impact funds as well as investing the money raised in companies that want to solve societal problems. He shares his views on how investments aimed at improving the health of the most vulnerable populations in the world can still generate adequate financial returns for the investors.
https://www.ucb.com
https://healthquad.in
Offering a 10$ DNA based diagnostic test for blood disorders and cancer. Anna Shuh is a medical doctor, an academic researcher, and a healthcare entrepreneur. She started working at Oxford University in 2006 as the clinical director of the haematology lab at Oxford University Hospitals. In 2014, she was appointed as Professor of Molecular Diagnostics. More recently, Anna joined the Muhimbili University for Health and Allied Sciences faculty in Tanzania and co-founded a social enterprise, Seren.
Seren is a social enterprise spin out of Oxford University and aims to promote and support diagnostics in low- and middle-income countries with an initial focus on DNA based tests for blood disorders and cancers. Historically, DNA sequencing required expert staff and high-tech equipment; interpreting tests is slow and expensive, and blood data often needs to be sent overseas to be analysed. The first facility in Dar-es-Salaam has now opened and will offer DNA tests for as little as $10 using low cost and low maintenance equipment, while cloud-based data systems allow remote analysis by experts so that samples do not need to be sent abroad. To prepare for the transfer of all testing to SEREN, Oxford has provided training for laboratory technicians and health professionals from five hospitals in Tanzania and Uganda.
MSc in International Health and Tropical Medicine (IHTM) - https://www.tropicalmedicine.ox.ac.uk/study-with-us/msc-ihtm
Health Innovation and Entrepreneurship
Charles Antoine Janssen shares his views on how investments aimed at improving the health of the most vulnerable populations in the world can still generate adequate financial returns for the investors. Charles Antoine Janssen is vice chair of UCB, a global biopharmaceutical company headquartered in Belgium. And he's also managing partner of Kois https://koisinvest.com and Healthquad. Charles Antoine has experience in fundraising for social impact funds as well as investing the money raised in companies that want to solve societal problems. He shares his views on how investments aimed at improving the health of the most vulnerable populations in the world can still generate adequate financial returns for the investors.
https://www.ucb.com
https://healthquad.in
